A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098
- Conditions
- Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)
- Interventions
- Registration Number
- NCT05473195
- Lead Sponsor
- TASK Applied Science
- Brief Summary
To evaluate the 7-day early bactericidal activity (EBA), pharmacokinetics (PK), safety and tolerability of ethionamide (Eto) with or without BVL-GSK098 in participants with rifampicin- and isoniazid-susceptible pulmonary TB.
- Detailed Description
A single-centre, open-label, clinical trial in two stages. All treatments will be administered orally (PO) on days 1-7.
Stage 1 will recruit 15 participants into arm 1 who will receive Eto and a low dose BVL-GSK098 combination (bEto), including 3 participants from the control arm (arm 2). Participants will be randomized 5:1. This will be followed by a recruitment pause and an interim analysis to evaluate safety of the combination.
Stage 1:
Arm Regimen Participants
1. BVL-GSK098 9 mg once daily (OD) plus ethionamide 250 mg OD (b9Eto250) 15
2. Isoniazid 300 mg po OD (INH) 3 \* BVL-GSK098 9 mg will be given 12-hourly on Day one (loading dose), then once daily on Day 2-7.
An interim safety analysis will be performed after all Stage 1 participants complete the end of treatment visit (Day 8). If the b9Eto250 arm meets the predefined safety criteria (Section 9), the study will proceed to Stage 2. Recruitment will then continue with the remaining arms randomized in a 4:5:5:5:5:5 ratio.
Stage 2:
Arm Regimen Participants 2 Isoniazid 300 mg po OD (INH) 12 3 BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125) 15 4 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) 15 5 BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500) 15 6 Ethionamide 250 mg po OD (Eto250) 15 7 Ethionamide 750 mg po given in a single or divided dose daily (Eto750) 15
\* BVL-GSK098 27 mg will be given 12-hourly on Day one (loading dose), then once daily on Day 2-7. Ethionamide 750 mg given in divided doses Day 1-3, and OD Day 4-7.
Participants on INH will serve as control for the EBA quantitative mycobacteriology. The study will not be blinded but the mycobacteriology laboratory staff performing the endpoint assays will remain blinded until analysis of the EBA results.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 106
- Participants are required to meet all the following criteria in order to be randomized.
- Provide written, informed consent prior to all trial-related procedures.
- Male or female, aged between 18 and 65 years, inclusive.
- Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive.
- Newly diagnosed and untreated pulmonary TB.
- Rifampicin- and isoniazid-susceptible pulmonary TB as determined by molecular testing (GeneXpert XDR or Genotype MTBDRplus for INH).
- A chest X-ray taken during the screening period or up to 2 weeks before screening which, in the opinion of the investigator, is consistent with TB.
- GeneXpert positive with a quantitative readout of medium or high.
- Ability to produce an adequate volume of sputum as estimated from an overnight sputum collection sample (estimated 10 ml or more).
- Be of non-childbearing potential or using effective methods of birth control.
- For WOCBP, injectable or other contraceptive methods (per Appendix 1) need to be given prior to or during screening, and at least 2 days prior to first dose of IP.
-
Participants will be excluded from participation if they fulfil any of the following criteria.
Medical History
-
Evidence of clinically significant conditions or findings, other than TB, that might compromise safety or the interpretation of trial endpoints, per discretion of the investigator.
-
History of epilepsy, seizures or other neuropsychiatric disorders that might compromise safety or the interpretation of trial endpoints, per discretion of the investigator
-
History of hypothyroidism
-
QTcF of >450 ms at baseline
-
Clinically significant evidence of extrathoracic TB, as judged by the investigator.
-
History of allergy to any of the trial IP as confirmed by the clinical judgement of the investigator.
-
Alcohol or drug abuse, that in the opinion of the investigator, is sufficient to compromise the safety or cooperation of the participant.
-
HIV positive AND:
- CD4 < 250cells/mm3
- OR, on ART in stage 1 only. Participants established on ART (2 NRTIs and dolutegravir) for more than 30 days at start of screening are eligible for participation in stage 2.
NOTE: ART permitted in Stage 2 is limited to the following in line with local guidelines for 1st line ART:
- NRTIs selected from: Emtricitabine, Lamivudine, Tenofovir
- PLUS Dolutegravir
As the drug-drug interaction potential of ART has not been fully investigated with the IP, NNRTIs (efavirenz, nevirapine) and other protease inhibitors will not be permitted in this study.
-
Female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of trial participation. Male participant planning to conceive a child for at least 90 days, after the last dose of study intervention in the trial.
Treatment History
-
Participation in other clinical studies with investigational agents within 8 weeks prior to screening.
-
Treatment received for this episode of TB with any drug active against M.tb (including but not limited to isoniazid, ethambutol, amikacin, cycloserine, fluoroquinolones, rifabutin, rifampicin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, pyrazinamide, thioacetazone, capreomycin, thioamides).
-
Treatment with immunosuppressive medications such as TNF-alpha inhibitors within 2 weeks prior to screening, or systemic corticosteroids for more than 7 days within 2 weeks prior to screening.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm 6 Ethionamide 250 mg Ethionamide 250 mg po OD (Eto250) Arm 4 Ethionamide 250 mg BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) Arm 3 Ethionamide 250mg BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125) Arm 5 Ethionamide 250mg BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500) Arm 1 Ethionamide 250mg BVL-GSK098 9 mg once daily (OD) plus ethionamide 250 mg OD (b9Eto250) Arm 7 Ethionamide 250mg Ethionamide 750 mg po given in a single or divided dose daily (Eto750) Arm 3 BVL-GSK098 9mg BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125) Arm 4 BVL-GSK098 9mg BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) Arm 1 BVL-GSK098 9mg BVL-GSK098 9 mg once daily (OD) plus ethionamide 250 mg OD (b9Eto250) Arm 2 Isoniazid 300 MG Isoniazid 300 mg po OD (INH)
- Primary Outcome Measures
Name Time Method EBA CFU 7 days The EBA CFU(0-7) as determined by the predicted rate of change in log10CFU per ml sputum over the period day 0 to day 7 will be described using linear, bi-linear or non-linear functions using nonlinear mixed effects modelling as dictated by the data of log10CFU over time and relation to drug exposure.
Predicted estimate of rates of change including uncertainties for the potential differences in treatment effects between the groups will be given and graphically illustrated.
- Secondary Outcome Measures
Name Time Method EBA TTP 7 days The EBA TTP(0-7) as determined by the predicted rate of change in TTP over the period day 0 to day 7 will be described using linear, bi-linear or non-linear functions using nonlinear mixed effects modelling of TTP over time and relation to drug exposure.
Trial Locations
- Locations (1)
TASK Clinical Research Centre
🇿🇦Cape Town, Western Cape, South Africa